EBMT 2019 | The TRANSCEND-CLL-004 study: JCAR017

Name: The TRANSCEND-CLL-004 study: JCAR017
Uploaded: 2019-03-26T12:00:58.000Z
Duration: 4 min
Description: Tanya Siddiqi, MD, from the City of Hope National Medical Center, Duarte, CA, provides updates from the Phase I TRANSCEND-CLL-004 study (NCT03331198) for relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Siddiqi was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Tanya Siddiqi • 26 Mar 2019

EBMT 2019

General CAR-T Lisocabtagene maraleucel

TRANSCEND-CLL-004

Tanya Siddiqi, MD, from the City of Hope National Medical Center, Duarte, CA, provides updates from the Phase I TRANSCEND-CLL-004 study (NCT03331198) for relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Siddiqi was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.